Michael J. Eckart

2.9k total citations
13 papers, 928 citations indexed

About

Michael J. Eckart is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Michael J. Eckart has authored 13 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Michael J. Eckart's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Michael J. Eckart is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Michael J. Eckart collaborates with scholars based in Germany, Austria and United States. Michael J. Eckart's co-authors include Jana Berger, Andréas Mackensen, Dimitrios Mougiakakos, Regina Jitschin, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst, Clemens‐Martin Wendtner, Raymonde Busch and Kirsten Fischer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Blood Advances.

In The Last Decade

Michael J. Eckart

12 papers receiving 912 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael J. Eckart Germany 7 648 507 397 195 181 13 928
Hari P. Miskin United States 15 699 1.1× 676 1.3× 297 0.7× 262 1.3× 189 1.0× 66 1.1k
Shuhua Cheng United States 14 341 0.5× 297 0.6× 332 0.8× 229 1.2× 136 0.8× 27 755
Larry Mansouri Sweden 19 591 0.9× 397 0.8× 307 0.8× 394 2.0× 79 0.4× 37 944
Justin C. Boysen United States 11 393 0.6× 249 0.5× 346 0.9× 218 1.1× 106 0.6× 24 681
Zoltán Mátrai Hungary 10 429 0.7× 289 0.6× 214 0.5× 140 0.7× 75 0.4× 30 561
Michael Voralia Canada 11 263 0.4× 309 0.6× 149 0.4× 229 1.2× 263 1.5× 25 681
Maurice Navarro France 6 357 0.6× 320 0.6× 187 0.5× 59 0.3× 94 0.5× 13 500
Annette M. Staiger Germany 14 224 0.3× 490 1.0× 109 0.3× 190 1.0× 18 0.1× 27 714
Takashi Akasaka Japan 15 229 0.4× 323 0.6× 120 0.3× 222 1.1× 92 0.5× 45 660
Feifei Nan China 16 78 0.1× 399 0.8× 275 0.7× 246 1.3× 37 0.2× 38 794

Countries citing papers authored by Michael J. Eckart

Since Specialization
Citations

This map shows the geographic impact of Michael J. Eckart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Eckart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Eckart more than expected).

Fields of papers citing papers by Michael J. Eckart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Eckart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Eckart. The network helps show where Michael J. Eckart may publish in the future.

Co-authorship network of co-authors of Michael J. Eckart

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Eckart. A scholar is included among the top collaborators of Michael J. Eckart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Eckart. Michael J. Eckart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Goede, Valentin, Kirsten Fischer, Sandra Robrecht, et al.. (2025). Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia. Blood Advances. 9(10). 2431–2435. 1 indexed citations
2.
Riecke, Armin, Eugen Tausch, Deyan Y. Yosifov, et al.. (2023). Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial. Blood. 142(Supplement 1). 199–199.
3.
4.
Langerbeins, Petra, Jasmin Bahlo, Paula Cramer, et al.. (2015). Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood. 126(23). 2934–2934. 4 indexed citations
5.
Jitschin, Regina, Martina Braun, Maike Büttner, et al.. (2014). CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 124(5). 750–760. 208 indexed citations
6.
Pflug, Natali, Jasmin Bahlo, Tait D. Shanafelt, et al.. (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 124(1). 49–62. 182 indexed citations
7.
Jitschin, Regina, Heiko Bruns, Andreas Gießl, et al.. (2014). Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 123(17). 2663–2672. 159 indexed citations
8.
9.
Fischer, Kirsten, Paula Cramer, Raymonde Busch, et al.. (2011). Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology. 29(26). 3559–3566. 271 indexed citations
10.
Fischer, Kirsten, Stephan Stilgenbauer, Carmen D. Schweighofer, et al.. (2008). Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). Blood. 112(11). 330–330. 71 indexed citations
11.
Bergmann, Manuela A., Barbara Eichhorst, Raymonde Busch, et al.. (2007). Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).. Blood. 110(11). 625–625. 17 indexed citations
12.
Wein, A., T Lehnert, Torsten Liersch, et al.. (2004). Toxicity and safety of weekly high-dose 5-FU as 24-h infusion and folinic acid (AIO regimen) in adjuvant therapy of UICC stage III colon cancer. InTACT: A multicenter phase III trial. Journal of Clinical Oncology. 22(14_suppl). 3586–3586. 1 indexed citations
13.
Wein, A., T Lehnert, Torsten Liersch, et al.. (2004). Toxicity and safety of weekly high-dose 5-FU as 24-h infusion and folinic acid (AIO regimen) in adjuvant therapy of UICC stage III colon cancer. InTACT: A multicenter phase III trial. Journal of Clinical Oncology. 22(14_suppl). 3586–3586. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hari P. Miskin Breakdown of academic impact, for papers by Shuhua Cheng Breakdown of academic impact, for papers by Larry Mansouri Breakdown of academic impact, for papers by Justin C. Boysen Breakdown of academic impact, for papers by Zoltán Mátrai Breakdown of academic impact, for papers by Michael Voralia Breakdown of academic impact, for papers by Maurice Navarro Breakdown of academic impact, for papers by Annette M. Staiger Breakdown of academic impact, for papers by Takashi Akasaka Breakdown of academic impact, for papers by Feifei Nan
Rankless by CCL
2026